Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Cereal grain scientists, ... will gather October 5–8, 2014, for the AACC ... Convention Center in Providence, Rhode Island. The comprehensive ... of food scientists, chemists, microbiologists, nutritionists, and those ... production management. To date, 1,000 attendees have registered ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the ... treated in a Phase 1b clinical trial of ... a proprietary small molecule,inhibitor of thioredoxin, a protein ... growth, survival and drug resistance of,many cancers., ...
... to Healthcare Organizations through CSC,s ... ... CSC (NYSE: CSC ) today,announced that its enterprise ... FirstPortfolio offering.,FirstPoint streamlines a health organization,s document management,processes and incorporates ...
... (OTC BB BSTC.OB-News) today announced that it sold ... stock priced at $15,per share for aggregate proceeds ... certain private investors on June 9, 2008. The ... at a premium over the,market price., BioSpecifics ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3CSC Adds Content Management to Hosted Healthcare Offering 2
(Date:9/21/2014)... years, new strains of bacteria have emerged that resist ... including drug-resistant forms of tuberculosis and staphylococcus, infect more ... 23,000. Despite the urgent need for new treatments, scientists ... the past decade. , MIT engineers have now turned ... gene-editing system that can disable any target gene, they ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... imaging technique to track the effects of next-generation nanomedicines ... Strathclyde academic. Professor Dr. M. N. V. Ravi ... of Pharmacy and Biomedical Sciences, believe an advanced form ... boost developments in the field of nanomedicines, the encapsulation ...
... the collaboration between Janssen, J&J Innovation, VIB, KU Leuven ... in translating basic molecular insights to diagnostics and therapeutics ... are committing up to 5 million Euros for this ... research projects from VIB, KU Leuven and UZ Leuven. ...
... obesity, endocrine-disrupting chemicals, adolescent health and clinical trials will be ... The 95th Annual Meeting & Expo of The Endocrine Society. ... 15 Adolescent Health (10 a.m. PDT): New insights ... conditions including eating disorders and gender identity disorder. ...
Cached Biology News:Nanomedicines' impact on patients under the microscope 2Nanomedicines' impact on patients under the microscope 3Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases 2
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... 2800mL PYREX Fernbach-style culture flasks have triple ... flask bottom to achieve maximal oxygen transfer ... large marking spot., A wide range of ... including:, Polypropylene colored caps for ease ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Biology Products: